Navigation Links
Blood Pressure Drug Does Not Help Those With Atrial Fibrillation
Date:3/9/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, March 9 (HealthDay News) -- The blood pressure-lowering drug Avapro doesn't seem to prevent heart disease and stroke in patients suffering from the irregular heartbeat called atrial fibrillation, a new Canadian study finds.

People with atrial fibrillation are at risk for heart disease and stroke, and lowering blood pressure is one way of staving off these potential problems. Avapro (irbesartan) is an angiotensin-receptor blocker, which lowers blood pressure by helping blood vessels dilate.

"Atrial fibrillation affects between 2 and 6 million men and women in the United States," said Dr. Gregg Fonarow, a spokesman for the American Heart Association and a professor of cardiology at the University of California, Los Angeles.

"Individuals with atrial fibrillation have substantially increased risk for stroke, other cardiovascular events, hospitalizations, and health-care expenditures," he added.

It has been "widely speculated" that angiotensin-receptor blockers might reduce the likelihood of recurrent atrial fibrillation and reduce the risk of cardiovascular events, Fonarow explained.

Earlier studies have suggested that angiotensin-receptor blockers benefit patients with atrial fibrillation, he added.

The latest report is published in the March 10 issue of the New England Journal of Medicine.

For the study, Dr. Salim Yusuf, from McMaster University in Hamilton, and colleagues randomly assigned 9,016 patients with atrial fibrillation to daily doses of Avapro or a placebo. Over about four years of follow-up, the researchers looked for incidents of stroke, heart attack, death and heart failure.

The researchers found that even though people taking Avapro had lower blood pressure than those taking placebo, people in both groups suffered a stroke, heart attack or died at the same rate over the four years.

In addition, those taking Avapro or placebo suffered heart failure at about the same rate, but those taking Avapro had a lower rate of hospitalization for heart failure, the researchers said. Also, there was no benefit from the drug among patients with a normal heart rhythm at the start of the study when it came to preventing hospitalization for atrial fibrillation.

The researchers also found more patients taking Avapro had blood pressure that was too low and more had kidney failure than did those receiving a placebo.

"This study demonstrates Avapro, despite a modest reduction in blood pressure, does not prevent recurrent episodes of atrial fibrillation or prevent cardiovascular events overall," Fonarow said. "There were no differences in heart attacks, cardiovascular deaths or deaths from any cause. There were modestly lower rates of hospitalization for heart failure and any cardiovascular hospitalization."

When this new trial is considered together with an earlier trial, it's evident that this class of blood pressure drugs has no effect in preventing episodes of atrial fibrillation in patients with intermittent atrial fibrillation, he added.

"In the absence of other indications, routine use of angiotensin-receptor blockers in patients with atrial fibrillation does not appear to be warranted," Fonarow said.

More information

For more on atrial fibrillation, visit the American Heart Association.

SOURCES: Gregg Fonarow, M.D., spokesman, American Heart Association, and professor, cardiology, University of California, Los Angeles; March 10, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Redefining normal blood pressure
2. University of South Florida researchers find blood-brain barrier damaged by disease
3. Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders
4. OHSU physician explores method to reduce blood-clot risk in trauma patients
5. University of Nevada, Reno, teams with IMMY to make new life-saving blood test
6. Tight Blood Sugar Control May Put Some Diabetics at Risk
7. Napping May Help Keep Blood Pressure in Check
8. Blood Pressure Drugs May Help Heart Patients Without Hypertension
9. Dramatic Drop in Blood Infections Among ICU Patients: CDC
10. A small subset of normal white blood cells gives rise to a rare leukemia, study shows
11. Simple blood test at discharge could help reduce hospital readmissions for heart failure patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood Pressure Drug Does Not Help Those With Atrial Fibrillation 
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... ... innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ program ... each prescription referral received at our specialty pharmacy. , “Since our Pay ...
(Date:2/9/2016)... ... 2016 , ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, ... furnace not producing any heat. Shortly after entering the home, Paul was able to ... dangerous levels of carbon monoxide into the home, at 2,000 parts per million in ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton ... and Younkers department stores, announced it has raised $176,000 to benefit the Breast ... Comprehensive Cancer Center at the University of Iowa, The Lynn Sage Cancer Research ...
(Date:2/9/2016)... ... February 09, 2016 , ... ZipHearing.com ... access to affordable hearing aids , increase industry transparency, and promote awareness ... United States. , “For the average consumer, the hearing aid industry is esoteric ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... products, announced today the introduction of the newly designed, innovative shoulder wrap. ... better cold therapy coverage for the injured arm and shoulder to promote faster ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Aesthetic Devices - Medical Devices Pipeline Assessment, ... "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" provides ... This report is prepared using data ... GlobalData,s team of industry experts. *Note: Certain sections ... on the availability and relevance of data in relation ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
(Date:2/8/2016)... , Feb. 8, 2016  Echo ... medical device company focused on non-invasive continuous ... announced today announced that it will host ... February 17, 2015 at 9:00 a.m. Eastern ... discuss its corporate strategy, advancements in its ...
Breaking Medicine Technology: